TABLE 1

Baseline demographics, clinical characteristics, and outcomes of the efficacy population

ParameterValue for group
Overall (n = 126)Monotherapy (n = 89)Combination therapy (n = 37)
Demographics
    Median age (yr) (IQR)59 (45.5–66.8)59 (48–67)57 (45–66.5)
    No. of male patients (%)70 (55.6)50 (56.2)20 (54.1)
    No. of patients of race (%)
        African American86 (68.3)62 (69.7)24 (64.9)
        Caucasian34 (27.0)21 (23.6)13 (35.1)
        Hispanic/Latino1 (0.8)1 (1.1)0
        Other5 (4.0)5 (5.6)0
    No. of patients in hospital system (%)
        Detroit Medical Center83 (65.9)52 (58.4)31 (83.8)
        UF Health-Shands Hospital30 (23.8)26 (29.2)4 (10.8)
        Henry Ford Hospital13 (10.3)11 (12.4)2 (5.4)
Comorbidities and past medical history
    No. of patients with comorbidity or past medical history (%)
        Prior antibiotics (90 days)33 (26.2)24 (27.0)9 (24.3)
        Prior MRSA infection (1 yr)20 (15.9)14 (15.7)6 (16.2)
        Obesity48 (38.1)37 (41.6)11 (29.7)
        Diabetes mellitus47 (37.3)34 (38.2)13 (35.1)
        Chronic kidney disease34 (27.0)25 (28.1)9 (24.3)
        Chronic hemodialysis26 (20.6)19 (21.3)7 (18.9)
        Liver disease20 (15.9)13 (14.6)7 (18.9)
        Intravenous drug user24 (19.0)14 (15.7)10 (27.0)
        Malignancy7 (5.6)4 (4.5)3 (8.1)
        HIV/AIDS8 (6.3)3 (3.4)5 (13.5)
        Neutropeniaa3 (2.4)2 (2.2)1 (2.7)
    Median Charlson comorbidity index (IQR)3 (2–5)3 (2–5)3 (2–5)
Clinical characteristics
    No. of patients in intensive care unit (%)b45 (35.7)31 (34.8)14 (37.8)
    Median APACHE II score (IQR)b16 (12–22)16 (12–22)16 (13–22)
    No. (%) of patients with:
        Lower respiratory tract source41 (32.5)30 (33.7)11 (29.7)
        Infective endocarditis source31 (24.6)20 (22.5)11 (29.7)
        Bone/joint source26 (20.6)20 (22.5)6 (16.2)
        Intravenous catheter source20 (15.9)16 (18.0)4 (10.8)
        Skin/soft tissue source11 (8.7)9 (10.1)2 (5.4)
        Other source22 (17.5)14 (15.7)8 (21.6)
        Polymicrobial BSI10 (7.9)6 (6.7)4 (10.8)
        Vancomycin-susceptible strainc125 (99.2)88 (98.9)37 (100.0)
        Daptomycin-susceptible strainc,d116 (96.7)80 (96.4)36 (97.3)
        Ceftaroline-susceptible straine94 (96.9)70 (95.9)24 (100.0)
Treatment information
    No. (%) of patients with:
        Infectious diseases consultf113 (93.4)79 (91.9)34 (97.1)
        Source control pursuedg42 (34.7)28 (32.9)14 (38.9)
        Prior directed therapy with vancomycin107 (84.9)74 (83.1)33 (89.2)
        Prior directed therapy with daptomycin48 (38.1)22 (24.7)26 (70.3)
        Ceftaroline dosing frequency
            Every 8 h66 (52.4)52 (58.4)14 (37.8)
            Every 12 h54 (42.9)33 (37.1)21 (56.8)
            Every 24 h6 (4.8)4 (4.5)2 (5.4)
        Ceftaroline dose
            600 mg76 (60.3)55 (61.8)21 (56.8)
            400 mg19 (15.1)14 (15.7)5 (13.5)
            300 mg11 (8.7)8 (9.0)3 (8.1)
            200 mg20 (15.9)12 (13.5)8 (21.6)
    Median ceftaroline inpatient duration (days) (IQR)13 (5–21)13 (5–22)14 (4–17)
    No. (%) of patients receiving combination therapy with:
        Daptomycin28 (22.2)28 (75.7)
        Vancomycin3 (2.4)3 (8.1)
        Gentamicin3 (2.4)3 (8.1)
        Rifampin5 (4.0)5 (13.5)
Outcomes
    No. of patients achieving clinical success (%)86 (68.3)62 (69.7)24 (64.9)
    No. of patients with in-hospital mortality (%)28 (22.2)17 (19.1)11 (29.7)
    No. of patients with cleared BSI on ceftaroline (%)115 (91.3)79 (88.8)36 (97.3)
    Median BSI duration post-ceftaroline initiation (days) (IQR)3 (1–4)2 (1–4)3 (1.5–5)
    Median length of stay post-ceftaroline initiation (days) (IQR)12 (8–20)12 (8–18)15 (8.5–22.5)
  • a Defined as an absolute neutrophil count of <500 cells/mm3 at ceftaroline initiation.

  • b At the time of the index culture.

  • c Susceptibility determined by Microscan, Vitek 2, BD Phoenix, or Etest.

  • d Daptomycin susceptibility were available for 120, 83, and 37 patients in the efficacy population and the monotherapy and combination therapy subgroups, respectively.

  • e Ceftaroline susceptibility was determined by Etest for 97, 73, and 24 patients in the efficacy population and the monotherapy and combination therapy subgroups, respectively.

  • f Infectious diseases consult status known for 121, 86, and 35 patients in the efficacy population and the monotherapy and combination therapy subgroups, respectively.

  • g Pursuit of source control known for 121, 85, and 36 patients in the efficacy population and the monotherapy and combination therapy subgroups, respectively.